Literature DB >> 9225072

Does pharmacokinetic variability influence the efficacy of high-dose methotrexate for the treatment of children with acute lymphoblastic leukemia: what can we learn from small studies?

W E Evans1, M V Relling, J M Boyett, C H Pui.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9225072     DOI： 10.1016/s0145-2126(96)00128-2

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


× No keyword cloud information.
  4 in total

1.  Population pharmacokinetics of high-dose methotrexate in children with acute lymphoblastic leukaemia.

Authors:  Dolores Aumente; Dolores Santos Buelga; John C Lukas; Pedro Gomez; Antonio Torres; Maria José García
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 2.  From methotrexate to pemetrexed and beyond. A review of the pharmacodynamic and clinical properties of antifolates.

Authors:  Jackie Walling
Journal:  Invest New Drugs       Date:  2006-01       Impact factor: 3.651

3.  Evaluation of body-surface-area adjusted dosing of high-dose methotrexate by population pharmacokinetics in a large cohort of cancer patients.

Authors:  Usman Arshad; Max Taubert; Tamina Seeger-Nukpezah; Sami Ullah; Kirsten C Spindeldreier; Ulrich Jaehde; Michael Hallek; Uwe Fuhr; Jörg Janne Vehreschild; Carolin Jakob
Journal:  BMC Cancer       Date:  2021-06-20       Impact factor: 4.430

4.  Population Pharmacokinetics of High-Dose Methotrexate in Chinese Pediatric Patients With Acute Lymphoblastic Leukemia.

Authors:  Xuan Gao; Xiao-Wen Qian; Xiao-Hua Zhu; Yi Yu; Hui Miao; Jian-Hua Meng; Jun-Ye Jiang; Hong-Sheng Wang; Xiao-Wen Zhai
Journal:  Front Pharmacol       Date:  2021-07-13       Impact factor: 5.810
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.